HUMIRA® for HCPs
SkyRizi™ for HCPs
RINVOQ™ for HCPs

The IL-23 inhibitor from AbbVie indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy1

Committed to supporting an EXCEPTIONAL PATIENT EXPERIENCE with timely product access and educational resources

Skyrizi Complete logo

GIVING PATIENTS THE RESOURCES THEY NEED,
WHEN THEY NEED THEM

Enrolling your patients in Skyrizi Complete will provide your patients the support to start and stay on track with their prescribed treatment, including the resources below.

Skyrizi Complete empowers patients with nurse ambassadors

Empower Patients

Nurse Ambassadors*

Skyrizi Complete provides insurance support with access specialists

Insurance support when needed

Access Specialists

Help with access and treatment affordability with access and savings

Help with access & treatment affordability

Access & Savings

Nurse ambassadors are available to educate patients with insurance questions, savings opportunities, and provide support with training, after initial training by a qualified HCP.

Empower Patients

Nurse Ambassadors*

Our Nurse Ambassadors are the heart of SKYRIZI Complete

Nurse Ambassadors provide 1:1 support to help meet the unique needs of each individual patient, including:

  • Committed to answering questions throughout the injection experience to help avoid disruptions
  • Answer patients’ insurance questions, help them identify ways to save on prescription costs, and connect them with additional insurance expertise
  • After the patient has been trained in the doctor's office, registered nurses with an average of more than 19 years of experience can provide supplemental injection training2
  • For SKYRIZI patients, Nurse Ambassadors will also educate patients on their role in getting SKYRIZI to the office

Call 1-866-SKYRIZI (1-866-759-7494) to have your patient connect with a Nurse Ambassador


*Ambassadors do not provide medical advice and are trained to direct patients to speak with their healthcare professional about any treatment-related questions, including further referrals.

ACCESS SPECIALISTS HAVE EXPERTISE IN PAYER-SPECIFIC POLICIES AND PROCESSES:

  • Are knowledgeable on Medicare and commercial plans at a national, local, and program level
  • Can educate on payer prior authorization requirements and appeal processes so you can determine the best access solution for each patient’s unique situation
  • Can educate on potential options to consider based on each patient’s unique financial situation
  • Help navigate prescription delivery to ensure SKYRIZI is delivered to the office for the patient's appointment

Call to speak to an Access Specialist 1-877-COMPLETE (1-877-266-7538)

Insurance support is provided by new access specialists who can educate your practice on how to help patients get access to SKYRIZI

Insurance support when needed

Access specialists

While SKYRIZI coverage is being established Skyrizi Complete may help patients access treatment

Help with access & treatment affordability

Access & Savings

SKYRIZI Complete can help your commercial patients save:

  • With the Skyrizi Complete Savings Card, your eligible commercially insured patients may pay as little as $5 per quarterly dose. Terms and Conditions apply.
  • Skyrizi Complete may help eligible commercially insured patients experiencing initial coverage delays or denials access their prescribed therapy at no charge while coverage is established. Eligibility criteria apply; call 1-866-SKYRIZI (1-866-759-7494) for more information. Terms and Conditions apply.
  1. Terms and Conditions apply. This benefit covers SKYRIZI™ (risankizumab). Eligibility: Available to patients with commercial prescription insurance coverage for SKYRIZI who meet eligibility criteria. Copay assistance program is not available to patients receiving prescription reimbursement under any federal, state, or government-funded insurance programs (for example, Medicare [including Part D], Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs) or where prohibited by law or by the patient’s health insurance provider. If at any time a patient begins receiving prescription drug coverage under any such federal, state, or government-funded healthcare program, patient will no longer be able to use the Skyrizi Complete Savings Card and patient must call Skyrizi Complete at 1.866.SKYRIZI to stop participation. Patients residing in or receiving treatment in certain states may not be eligible. Patients may not seek reimbursement for value received from the Skyrizi Complete program from any third-party payers. Offer subject to change or discontinuance without notice. Restrictions, including monthly maximums, may apply. This is not health insurance.
  2. Program is not available to patients receiving prescription reimbursement under any federal, state, or government-funded insurance programs (for example, Medicare [including Part D], Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs) or where prohibited by law or by the patient’s health insurance provider. If at any time a patient begins receiving prescription drug coverage under any such federal, state, or government-funded healthcare program, patient will no longer be eligible to participate in program. Available to patients between the ages of 18-63 with commercial prescription insurance coverage who meet eligibility criteria. Eligibility: Patients must be diagnosed with moderate to severe plaque psoriasis, have a valid prescription for SKYRIZI and participate in a commercial insurance plan that has denied or not yet made a formulary decision for SKYRIZI. Once the patient’s insurance plan has made a formulary decision and established a process for reviewing coverage requests for SKYRIZI, continued eligibility for the program requires the submission of a Prior Authorization prior to the next scheduled dose and appeal of the coverage denial within 180 days. Program provides SKYRIZI at no charge to patients for up to 2 years or until they receive insurance coverage approval, whichever occurs earlier. Offer subject to change or discontinuance without notice. This is not health insurance and program does not guarantee insurance coverage.
Skyrizi Complete App logo

Patients can track treatment with the

Skyrizi Complete App


The Complete App helps patients set reminders, prepare for upcoming doses, and access additional resources.

Download on the App Store
Get It On Google Play

STREAMLINE RX PROCESS FOR PATIENTS

Completepro.com


CompletePro.com can be used for Skyrizi Complete enrollment, electronic benefits verification and prior authorization, reauthorization, shipment tracking, and more to help your patients quickly start and stay on track with therapy.

Watch how Complete Pro can smooth the prescription process for your patients

Stay up to date on the latest SKYRIZI news and information


Sign up to receive the latest SKYRIZI news and information

See SkyriziResults

after 1 dose

View patient case studies, clinical efficacy with results after 1 dose

Helpful resources for your practice and your patients

SKYRIZI resources

Find out more about Skyrizi Complete resources for your patients
IMPORTANT SAFETY INFORMATION AND INDICATION FOR SKYRIZI™ (risankizumab-rzaa) 1
Indication

SKYRIZI is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

Important Safety Information

Infection

SKYRIZI may increase the risk of infection. Do not initiate treatment with SKYRIZI in patients with a clinically important active infection until it resolves or is adequately treated.

In patients with a chronic infection or a history of recurrent infection, consider the risks and benefits prior to prescribing SKYRIZI. Instruct patients to seek medical advice if signs or symptoms of clinically important infection occur. If a patient develops such an infection or is not responding to standard therapy, closely monitor and discontinue SKYRIZI until the infection resolves.

Pre-Treatment Evaluation for Tuberculosis (TB)

Prior to initiating treatment with SKYRIZI, evaluate for TB infection and consider treatment in patients with latent or active TB for whom an adequate course of treatment cannot be confirmed. Monitor patients for signs and symptoms of active TB during and after SKYRIZI treatment. Do not administer SKYRIZI to patients with active TB.

Immunizations

Prior to initiating SKYRIZI, consider completion of all age appropriate immunizations according to current immunization guidelines.

Avoid use of live vaccines in patients treated with SKYRIZI.

Adverse Reactions

Most common (≥1 %) adverse reactions associated with SKYRIZI include upper respiratory infections, headache, fatigue, injection site reactions, and tinea infections.

Please see Full Prescribing Information.

US-SKZD-190350

REFERENCES

  1. SKYRIZI [package insert]. North Chicago, IL: AbbVie Inc.
  2. Data on file, AbbVie Inc. HUMIRA Complete Metrics. February 2019.
IMPORTANT SAFETY INFORMATION AND INDICATION FOR SKYRIZI™ (risankizumab-rzaa)1
Infection SKYRIZI™ may increase the risk of infection. Do not initiate treatment with SKYRIZI in patients with a clinically important active infection until it resolves or is adequately treated. Prior to initiating treatment with SKYRIZI, evaluate for TB infection and consider treatment in patients with latent or active TB for whom an adequate course of treatment cannot be confirmed. Monitor patients for signs and symptoms of active TB during and after SKYRIZI treatment. Do not administer SKYRIZI to patients with active TB.
IMPORTANT SAFETY INFORMATION AND INDICATION FOR SKYRIZI™ (risankizumab-rzaa)1
Infection SKYRIZI™ may increase the risk of infection. Do not initiate treatment with SKYRIZI in patients with a clinically important active infection until it resolves
IMPORTANT SAFETY INFORMATION AND INDICATION FOR SKYRIZI™ (risankizumab-rzaa)1
Infection SKYRIZI™ may increase the risk of infection. Do not initiate treatment with SKYRIZI in patients with a clinically important active infection until it resolves or is adequately treated. Prior to initiating treatment with SKYRIZI, evaluate for TB infection and consider treatment in patients with latent or active TB for whom an adequate course of treatment cannot be confirmed. Monitor patients for signs and symptoms of active TB during and after SKYRIZI treatment. Do not administer SKYRIZI to patients with active TB.
IMPORTANT SAFETY INFORMATION AND INDICATION FOR SKYRIZI™ (risankizumab-rzaa)1
Infection SKYRIZI™ may increase the risk of infection. Do not initiate treatment with SKYRIZI in patients with a clinically important active infection until it resolves
IMPORTANT SAFETY INFORMATION AND INDICATION FOR SKYRIZI™ (risankizumab-rzaa) 1
Indication

SKYRIZI is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

Important Safety Information

Infection

SKYRIZI may increase the risk of infection. Do not initiate treatment with SKYRIZI in patients with a clinically important active infection until it resolves or is adequately treated.

In patients with a chronic infection or a history of recurrent infection, consider the risks and benefits prior to prescribing SKYRIZI. Instruct patients to seek medical advice if signs or symptoms of clinically important infection occur. If a patient develops such an infection or is not responding to standard therapy, closely monitor and discontinue SKYRIZI until the infection resolves.

Pre-Treatment Evaluation for Tuberculosis (TB)

Prior to initiating treatment with SKYRIZI, evaluate for TB infection and consider treatment in patients with latent or active TB for whom an adequate course of treatment cannot be confirmed. Monitor patients for signs and symptoms of active TB during and after SKYRIZI treatment. Do not administer SKYRIZI to patients with active TB.

Immunizations

Prior to initiating SKYRIZI, consider completion of all age appropriate immunizations according to current immunization guidelines.

Avoid use of live vaccines in patients treated with SKYRIZI.

Adverse Reactions

Most common (≥1 %) adverse reactions associated with SKYRIZI include upper respiratory infections, headache, fatigue, injection site reactions, and tinea infections.

Please see Full Prescribing Information.

US-SKZD-190350